Palbociclib is a highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6), which has been approved by the US Food and Drug Administration (FDA) to treat hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−) breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.